COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Intranasal Treatment of HIV-associated Neurocognitive Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03277222
Recruitment Status : Terminated (Unable to find further eligible participants)
First Posted : September 8, 2017
Last Update Posted : June 11, 2020
Canadian Institutes of Health Research (CIHR)
University of Alberta
Epidemiology Coordinating and Research Centre, Canada
Information provided by (Responsible Party):
John Gill, University of Calgary

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : April 21, 2019
Actual Study Completion Date : April 21, 2019
Fujiwara, E., Gill, J.M. & Power, C. Risk Factors for HIV-Associated Neurocognitive Disorders (HAND) in a Canadian Cohort (P1.321). Neurology 86 P1.321 (2016).
Sacktor, N., et al. Paroxetine and Fluconazole Therapy for HAND: A Double-Blind, Placebo-Controlled Trial. Conference on retroviruses and opportunistic infections. 2016 Boston MA USA Sesssion O-12 Abstract 146(2016).